Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
New data from T. Miyagawa et al illuminate research in gene therapy
May 29th, 2008
"Herpes virus type 1 thymidine kinase (HSV1-tk) and the mutant HSV1-sr39tk are the 2 most widely used ''reporter genes'' for radiotracer-based imaging. Two pyrimidine nucleoside analogs, [F-18]FEAU (1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyl-uridine) and [F-18]FFEAU (1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-(2-f luoroethyl)uridine), have generated recent interest as potential new probes for imaging HSV1 -tk and HSV1 -sr39tk gene expression," scientists in the United States report. "We compared [F-18]FEAU and (F-18]FFEAU with a series of other pyrimidine nucleoside derivatives (including 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouridine...
Source: Gene Therapy Weekly (2008-05-29)
|
